MARKET

NKTR

NKTR

Nektar Therapeutics
NASDAQ
70.50
-3.84
-5.16%
Opening 15:48 05/15 EDT
OPEN
73.51
PREV CLOSE
74.33
HIGH
73.81
LOW
69.38
VOLUME
932.27K
TURNOVER
--
52 WEEK HIGH
109.00
52 WEEK LOW
7.99
MARKET CAP
2.38B
P/E (TTM)
-8.3753
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), BeOne Medicines (ONC) and Nektar Therapeutics (NKTR)
TipRanks · 1d ago
Healthcare stocks with A+ momentum investors are watching
Seeking Alpha · 3d ago
Nektar price target lowered to $80 from $95 at Wedbush
TipRanks · 4d ago
Nektar Therapeutics Price Target Cut to $80.00/Share From $95.00 by Wedbush
Dow Jones · 4d ago
Nektar Therapeutics Is Maintained at Neutral by Wedbush
Dow Jones · 4d ago
Wedbush Maintains Neutral on Nektar Therapeutics, Lowers Price Target to $80
Benzinga · 4d ago
NEKTAR THERAPEUTICS <NKTR.O>: WEDBUSH CUTS TARGET PRICE TO $80 FROM $95
Reuters · 4d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 4d ago
More
About NKTR
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.

Webull offers Nektar Therapeutics stock information, including NASDAQ: NKTR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NKTR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NKTR stock methods without spending real money on the virtual paper trading platform.